Psychiatrists' attitudes to maintenance medication for patients with schizophrenia

Psychological Medicine

Volumn 33, Issue 1, 2003, Pages 83-89

  Patel, M X ^a   Nikolaou, V ^a   David, A S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUPENTIXOL DECANOATE; HALOPERIDOL DECANOATE; LONG ACTING DRUG; NEUROLEPTIC AGENT; PIPOTIAZINE; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; BODY WEIGHT DISORDER; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; POSTAL MAIL; PRESCRIPTION; PSYCHIATRIST; QUESTIONNAIRE; RELAPSE; RELATIVE; SCHIZOPHRENIA; UNITED KINGDOM;

ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; CROSS-SECTIONAL STUDIES; DELAYED-ACTION PREPARATIONS; ENGLAND; FEMALE; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PSYCHIATRY; QUESTIONNAIRES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0037237469     PISSN: 00332917     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0033291702006797     Document Type: Article

References (43)

1. Adams, C. E., Fenton, M. K. P., Quraishi, S. & David, A. S. (2001). Systemic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry 179, 290-299.
2. Anderson, D. (1989). In defence of the depot clinic: the consumer's opinion. Psychiatric Bulletin 13, 177-179.
3. Barnes, T. R. & Curson, D.A. (1994). Long-term depot antipsychotics: a risk-benefit assessment. Drug Safety 10, 464-479.
4. Bennett, J., Done, J. & Hunt, B. (1995). Assessing the side-effects of antipsychotic drugs: a survey of CPN practice. Journal of Psychiatric and Mental Health Nursing 2, 177-182.
5. Bloch, Y., Mendlovic, S., Strumpinsky, S., Altshuler, A., Fennig, S. & Ratzoni, G. (2001). Injections of depot antipsychotic, medications in patients suffering from schizophrenia: do they hurt? Journal of Clinical Psychiatry 62, 855-859.
6. Davis, J. M., Matalon, L., Watanabe, M. D. & Blake, L. (1994). Depot antipsychotic drugs. Place in therapy. Drugs 47, 741-773.
7. Dencker, S. J. (1984). The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. Journal of Clinical Psychiatry 45, 22-27.
8. Dencker, S. J. & Axelsson, R. (1996). Optimising the use of depot antipsychotics. CNS Drugs 6, 367-381.
9. Desai, N., Huq, Z., Martin, S. D. & McDonald, G. (1999). Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. Advances in Therapy 16, 78-88.
10. Dunn, G. (1989). Design and Analysis of Reliability Studies: The Statistical Evaluation of Measurement Errors, p. 37. Edward Arnold: London.
11. Geddes, J., Freemantle, N., Harrison, P. & Bebbington, P. (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 321, 1371-1376.
12. Glazer, W. M. & Kane, J. M. (1992). Depot neuroleptic therapy: an underutilized treatment option. Journal of Clinical Psychiatry 53, 426-433.
13. Hoencamp, E., Knegtering, H., Kooy, J. J. & Van der Molen, A. E. (1995). Patient requests and attitude towards neuroleptics. Nordic Journal of Psychiatry 49 (suppl. 35), 47-55.
14. Johnson, D. A. (1984). Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. Journal of Clinical Psychiatry 45, 13-21.
15. Kane, J. M., Aguglia, E., Altamura, A. C., Ayuso Gutierrez, J. L., Brunello, N., Fleischhacker, W. W., Gaebel, W., Gerlach, J., Guelfi, J. D., Kissling, W., Lapierre, Y. D., Lindstrom, E., Mendlewicz, J., Racagni, G., Carulla, L. S. & Schooler, N. R. (1998). Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology 8, 55-66.
16. Kemp, R. & David, A. (1997). Insight and compliance. In Treatment Compliance and the Therapeutic Alliance in Serious Mental Illness (ed. B. Blackwell), pp. 61-84. Harwood Academic Publishers: Amsterdam.
17. Kissling, W. (1991). The current unsatisfactory state of relapse prevention in schizophrenic psychoses - suggestions for improvement. Clinical Neuropharmacology 14 (suppl. 2), S33-44.
18. Kissling, W. (1994). Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatrica Scandinavica Supplement 382, 16-24.
19. Levine, J., Schooler, N. R. & Cassano, G. B. (1979). The role of depot neuroleptics in the treatment of schizophrenic patients. Psychological Medicine 9, 383-386.
20. Marland, G. R. & Sharkey, V. (1999). Depot neuroleptics, schizophrenia and the role of the nurse: is practice evidence based? A review of the literature. Journal of Advanced Nursing 30, 1255-1262.
21. Medical Directory (2000). Vols. 1 and 2. 156th Edition. Informa Healthcare, a division of Informa Publishing Group Limited: London.
22. Medical Practitioners Approved for the Purposes of Section 12 (2) of the Mental Health Act 1983 (1999). South Thames Health Authorities.
23. Parker, G., Lambert, T., McGrath, J., McGorry, P. & Tiller, J. (1998). Neuroleptic management of schizophrenia: a survey and commentary on Australian psychiatric practice. Australian and New Zealand Journal of Psychiatry 32, 50-58.
24. Patel, M., David, A. & Nikolaou, V. (2002). Eliciting psychiatrists' beliefs about side effects of typical and atypical antipsychotic drugs. Schizophrenia Research 53 (suppl.), 170.
25. Patel, M. X. & David, A. S. (2002). Why aren't depots prescribed more often, and what can be done about it? British Journal of Psychiatry (in the press).
26. Pereira, S. & Pinto, R. (1997). A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatrica Scandinavica 95, 464-468.
27. Prescriber (2000). Mental health drugs: recent trends in prescribing. Prescriber 19th Oct. 2000.
28. O'Ceallaigh, S. & Fahy, T. A. (2001). Is there a role for the depot clinic in the modern management of schizophrenia? Psychiatric Bulletin 25, 481-484.
29. Quraishi, S. & David, A. (2000a). Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders. Cochrane Library, Issue 2. Update Software: Oxford.
30. Quraishi, S. & David, A. (2000b). Depot fluspirilene for schizophrenia. Cochrane Library, Issue 2. Update Software: Oxford.
31. Quraishi, S. & David, A. (2000c). Depot haloperidol decanoate for schizophrenia. Cochrane Library, Issue 2. Update Software: Oxford.
32. Quraishi, S. & David, A. (2000d). Depot perphenazine decanoate and enanthate for schizophrenia. Cochrane Library, Issue 2. Update Software: Oxford.
33. Quraishi, S. & David, A. (2000e). Depot pipothiazine palmitate and undeclynate for schizophrenia. Cochrane Library, Issue 2. Update Software: Oxford.
34. Quraishi, S., David, A. & Adams, C. E. (2000). Depot bromperidol decanoate for schizophrenia. Cochrane Library, Issue 2. Update Software: Oxford.
35. Remington, G. J. & Adams, M. E. (1995). Depot neuroleptic therapy: clinical considerations. Canadian Journal of Psychiatry 40 (suppl. 1), S5-11.
36. Sarfati, Y., Olivier, V. & Bouhassira, M. (1999). Utilisation des nouveaux antipsychotiques dans le traitement de la schizophrénie: une enquête européenne L'Encéphale XXV, 658-666.
37. Simpson, G. M. (1984). A brief history of depot neuroleptics. Journal of Clinical Psychiatry 45, 3-4.
38. Svedberg, B., Hallstrom, T. & Lutzen, K. (2000). The morality of treating patients with depot neuroleptics: the experience of community psychiatric nurses. Nursing Ethics 7, 35-46.
39. Tavcar, R., Dernovsek, M. Z. & Zvan, V. (2000). Choosing antipsychotic maintenance therapy-a naturalistic study. Pharmacopsychiatry 33, 66-71.
40. Taylor, D., Mir, S., Mace, S. & Hogman, G. (1999). Is cost a factor -II? A survey of psychiatrists and health authorities to determine the factors influencing the prescribing and funding of atypical antipsychotics. National Schizophrenia Fellowship: Surrey.
41. Thacker, S. (1996). The use of depot neuroleptics in the elderly: a survey. International Journal of Geriatric Psychiatry 11, 423- 427.
42. Walburn, J., Gray, R., Gournay, K., Quraishi, S. & David, A. S. (2001). Systematic Review of patient and nurse attitudes to depot antipsychotic medication. British Journal of Psychiatry 179, 300-307.
43. Wistedt, B. (1995). How does the psychiatric patient feel about depot treatment, compulsion or help? Nordic Journal of Psychiatry 49 (suppl. 35), 41-46.